Ignite Creation Date:
2025-12-17 @ 1:42 PM
Ignite Modification Date:
2025-12-23 @ 4:55 PM
Study NCT ID:
NCT06093061
Status:
RECRUITING
Last Update Posted:
2025-05-11
First Post:
2023-10-16
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Sponsor:
National Cancer Centre, Singapore
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-03
Start Date Type:
ACTUAL
Primary Completion Date:
2028-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-10
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-16
First Submit QC Date:
None
Study First Post Date:
2023-10-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-08
Last Update Post Date:
2025-05-11
Last Update Post Date Type:
ACTUAL